In pregnancy, the uterine vasculature undergoes dramatic vasodilatory adaptations. Previously, vascular endothelial growth factor (VEGF) has been shown to stimulate endothelial nitric oxide synthase (eNOS) in uterine artery endothelial cells (UAECs) derived from pregnant ewes to a greater extent than those from non-pregnant ewes in a manner not fully explained by changes in the phosphorylation of eNOS. In this study, we used Fura-2 Ca 2C imaging and arginine-to-citrulline conversion eNOS activity assays to assess the importance of VEGF-stimulated Ca 2C responses in pregnancy-related changes in NO production in UAEC. In this study, we show that pregnancy-induced changes in VEGF-stimulated Ca 2C responses could account in part for the greater capacity of VEGF to stimulate eNOS in UAECs from pregnant versus non-pregnant animals. VEGF-stimulated Ca 2C responses in UAECs from pregnant and non-pregnant animals were mediated through VEGF receptor 2 and were detected in roughly 15% of all cells. There were no pregnancyspecific differences in area under the curve or peak height. UAECs from pregnant animals were more consistent in the time to response initiation, had a larger component of extracellular Ca 2C entry, and were more sensitive to a submaximal dose of VEGF. In UAECs from pregnant and non-pregnant animals Ca 2C responses and eNOS activation were sensitive to the phospholipase C/inositol 1,4,5-trisphosphate pathway inhibitors 2-aminoethoxydiphenylborane and U73122. Thus, changes in VEGF-stimulated [Ca 2C ] i are necessary for eNOS activation in UAECs, and pregnancy-induced changes in Ca 2C responses could also in part explain the pregnancy-specific adaptive increase in eNOS activity in UAECs.
Introduction
Pregnancy is a time of dramatic vascular adaptation. Through initial angiogenesis and then sustained vasodilation, the pregnant uterus achieves the biggest drop in vascular resistance of any organ system. This in turn promotes a dramatic increase in maternal uterine blood flow to meet the needs of the growing fetus (Magness 1998) . Impaired vasodilator outputs, including nitric oxide (NO) and prostacyclin, have been implicated in hypertensive disorders of pregnancy, such as preeclampsia (reviewed in Sladek et al. (1997) , Bird et al. (2003) , Walsh (2004) and Valdes et al. (2009)) . A further understanding of the causes of vascular adaptation of pregnancy and its failure in associated gestational hypertensive disorders could also be informative with respect to generalized hypertension.
The isolation and culture of ovine uterine artery endothelial cells (UAEC) has allowed further mechanistic studies (Bird et al. 2000 , Di et al. 2001 , Cale & Bird 2006 , Gifford et al. 2006a ,b, Sullivan et al. 2006 , Grummer et al. 2009 , Yi et al. 2010a ), and we have developed a mechanistic model of the tightly regulated changes that underlie pregnancy-enhanced vasodilator production in the gravid uterus. Results from our studies to date have indicated that ATP (working through heptahelical P2Y2 receptors) and vascular endothelial growth factor (VEGF) (working through VEGF receptor 2 (VEGFR2)) in particular both stimulate comparatively low NO production in lutealphase non-pregnant ewes, but relatively higher production in late-gestational pregnant ewes. In the case of ATP, an increase in capacitative Ca 2C entry (CCE), mediated by an increase in connexin 43 coupling and taking the form of repeated [Ca 2C ] i bursts, is also observed during pregnancy, and this is clearly a major drive for enhanced NO output (Yi et al. 2010a (Yi et al. , 2011 . Our previous study of the effects of VEGF in UAEC failed to reveal evidence for activating phosphorylation events sufficient to explain enhanced NO output in response to VEGF during pregnancy (Grummer et al. 2009 ). Given that cell-cell coupling alters the general ability of the cell as a whole to mount CCE responses, other classes of hormones (besides ATP), such as VEGF may also trigger enhanced endothelial NO synthase (eNOS) activation through enhanced capacitative entry responses. If so, an alteration in CCE response with VEGF stimulation could at least partly explain greater NO output. While VEGF Ca 2C signaling has been studied in detail in a number of other cell types, there is little understanding of the changes in endothelial VEGF signaling that relate to eNOS activation during pregnancy adaptation. To that end, our study examines in detail VEGFdriven Ca 2C signaling as it relates to NO production in both the non-pregnant and pregnant states. We propose the hypothesis that VEGF stimulates a phospholipase C (PLC)-mediated Ca 2C response in UAEC in general, and that a pregnancy-related increase in the VEGF-stimulated Ca 2C entry response (i.e. during the CCE phase) occurs.
We further propose that enhanced Ca 2C entry is causally related to eNOS activation, and may explain the greater eNOS activation in UAEC from pregnant animals as previously observed by Grummer et al. (2009 Recombinant Orf virus VEGF-E was purchased from AngioProteomie (Boston, MA, USA). VEGFR tyrosine kinase inhibitor (VEGFRi; 4-((4 0 -chloro-2 0 -fluoro)phenylamino)-6,7-dimethoxyquinazoline, a reasonably selective inhibitor of VEGFR2 over VEGFR1; IC 50 Z100 nM and 2 mM respectively), 2-aminoethoxydiphenylborane (2-APB; a somewhat selective inositol 1,4,5-trisphosphate receptor (IP3R) inhibitor), and U73122 (a selective inhibitor of PLC activation) were purchased from EMD Millipore. PP2 (a selective inhibitor of SRC family kinases) was purchased from Enzo Life Sciences (Farmingdale, NY, USA), and U0126 (a selective inhibitor of MEK, a kinase known to directly phosphorylate ERK1 and ERK2) was from Promega Corp.
Isolation of UAEC
Procedures for animal handling and protocols for experimental procedures were approved by the University of Wisconsin-Madison Research Animal Care Committees of both the School of Medicine and Public Health and the College of Agriculture and Life Sciences and followed the recommended American Veterinary Medicine Association guidelines for humane treatment and euthanasia of laboratory farm animals. Uterine arteries were obtained from mixed Western breed NP sheep and pregnant ewes at 120-130 days of gestation during non-survival surgery, and UAECs were prepared as previously described (Bird et al. 2000 , Grummer et al. 2009 ) and stored in liquid nitrogen. For all subsequent experiments, the cells thawed for use were grown to near confluence in MEM containing 20% FBS, 1% penicillin-streptomycin, and 4 mg/ml gentamycin.
Fura-2 [Ca 2C ] i imaging studies
Pooled passage 4 cells were grown in 35-mm glass-bottom micro well dishes and imaged at 70% confluence. The cells were loaded with 5 mM Fura-2 AM in Krebs buffer at 37 8C for 45 min as performed previously (Yi et al. 2010a) . They were then incubated at room temperature for 30 min to allow the hydrolysis of ester, and imaging was performed exactly as previously described (Yi et al. 2010a) . Pretreatments were 25 min for VEGFR kinase inhibitor; 20 min for PP2, U0126, and U73122; and 5 min for 2-APB.
eNOS activation assay
Passage 3 cells stored in liquid N 2 were plated in T75 flasks. After growing to confluence, as mentioned earlier, the cells were passaged to 12-well dishes and grown for 24 h to approximately 80% confluence. The cells were preincubated in Krebs buffer (25 mM HEPES (pH 7.4), 125 mM NaCl, 5 mM KCl, 1 mM MgSO 4 , 1 mM KH 2 PO 4 , 6 mM glucose, and 2 mM CaCl 2 ) and eNOS activity was then assessed using the arginine-to-citrulline conversion assay exactly as used previously (Grummer et al. 2009 ). Following pretreatment with vehicle or antagonists as described for 5-min, cells were treated with or without agonists for 10 min.
Western blotting analyses
UAECs were passaged into 60-mm dishes and maintained for 24-48 h until approximately 80% confluent. Antagonists were added 5 min before the 10-min agonist treatment. At the end of stimulation, media were quickly aspirated and cells were snap-frozen in liquid N 2 . The cells were solubilized in lysis buffer (50 mM HEPES (pH 7.5), 4 mM Na 4 P 2 O 7 -10 H 2 O, 100 mM NaCl, 10 mM EDTA, 10 mM NaF, 2 mM Na 3 (VO 4 ) 2 , 1 mM phenylmethylsulfonylfluoride, 1% Triton X-100, 5 mg/ml leupeptin, and 5 mg/ml aprotinin), briefly sonicated, and centrifuged at 12 000 g for 5 min. Subsequently, western blotting of extracted proteins and detection of phosphorylated proteins using phosphorylation-state-specific antibodies were achieved using ECL detection exactly as described previously (Sullivan et al. 2006 , Grummer et al. 2009 ). Fig. 1A and B) . Figure 1C shows that, where observed, VEGF165 commonly gave a delayed response (Fig. 1C) taking from many seconds to minutes to initiate a detectable Ca 2C response. There was also no evidence of any synchronous [Ca 2C ] i burst responses in UAEC from pregnant animals in response to 10 ng/ml VEGF165 alone, in contrast to results described in our previous report of synchronized burst responses in UAEC from pregnant animals treated with ATP (Yi et al. 2010a) . Nonetheless, the timing of the onset of response was more tightly grouped in UAEC from pregnant animals (Fig. 1C) . When responses were further combined to show the average, the VEGF165-stimulated Ca 2C response in UAEC from pregnant animals tended to reach more defined early maxima and then return to basal, while in UAEC from non-pregnant animals the average responses tended to peak at a lower level but with a longer plateau (Fig. 1D ).
Statistical analysis
In Fig. 2 , we extend our analysis to show dose dependency of the percentage of cells responding to VEGF165. Notably, UAEC from pregnant animals showed a significantly greater rate of observed Ca 2C responses to VEGF165 than UAEC from non-pregnant animals at the sub-maximal dose of 1 ng/ml VEGF165, which is closer to the physiological range (Fig. 2) . Thereafter, in UAEC from pregnant animals there was no further significant difference between 1 and 10 ng/ml in recruitment of cells to produce a Ca 2C response (12 and 15% respectively). In contrast, UAEC from non-pregnant animals treated with 1 ng/ml VEGF165 showed a significantly lower cell recruitment for a clear Ca 2C response, although this response increased further up to the level observed for responders in UAEC from pregnant animals as the dose increased beyond the physiological range to 10 ng/ml (5 and 16% respectively, Fig. 2 ).
VEGFR2 mediates the Ca 2C response to VEGF165
To differentiate the role of VEGFR1 and VEGFR2 in the mediation of Ca 2C response, we repeated the challenge of Fura-2-loaded UAEC with PlGF and VEGF-E. Whereas VEGF165 binds both VEGFR1 and VEGFR2 (Zachary 2003) , PlGF1 binds only VEGFR1 (Zachary 2003) , and VEGF-E preferentially binds VEGFR2 (Ogawa et al. 1998 , Meyer et al. 1999 . This follows the same strategy employed previously (Grummer et al. 2009 ) to decipher the critical role of VEGFR2 in eNOS phosphorylation and activity. Notably, neuropilin-1 (a transmembrane receptor known to bind VEGF) was not detected in UAEC by western blotting in previous experiments (Grummer et al. 2009 ). In UAEC from pregnant animals, VEGF-E-treated cells behaved similarly to cells treated with VEGF165 in terms of the percentage of cells producing a Ca 2C response (Table 1) . Parameters measuring amplitude and duration, such as Ca 2C peak height and area under the curve (AUC), were also indistinguishable. In UAEC from non-pregnant animals, the Ca 2C response to VEGF-E was significantly greater than the response to VEGF165 both in terms of the percentage of cells responding and the AUC for each responding cell (Table 1 ). The cumulative effect of this manifested itself in a vastly larger mean AUC when using data from all cells measured, including non-responding cells (Table 1) . In contrast to VEGF-E, the VEGFR1-selective PlGF was only able to produce a negligible response in both UAEC from non-pregnant animals and UAEC from pregnant animals. Few cells (!2%) responded to PlGF and as a result descriptive analysis on the response shape was not undertaken. To further investigate the possible negative regulatory effect of VEGFR1 stimulation on UAEC from non-pregnant animals (since VEGF-E gives responses to VEGF165, PlGF1, and VEGF-E in UAEC from both non-pregnant and pregnant animals are all fully consistent with previously published results (Grummer et al. 2009) , indicating that VEGFR2 is the sole mediator of eNOS activation by the VEGF peptide family members. In UAEC from both non-pregnant and pregnant animals the VEGF165-stimulated Ca 2C response was blocked by the VEGFRi (Fig. 3) Fig. 5A and B respectively. U73122 efficiently blocked the VEGF165-stimulated Ca 2C response at 1 mM in both UAEC from both non-pregnant and pregnant animals, virtually . UAEC from non-pregnant and pregnant animals were treated with 0.1 ng/ml (nZ5 dishes for each condition), 1 ng/ml (nZ5 dishes for each condition), or 10 ng/ml VEGF165 (nZ8 dishes for each condition) and imaged for 30 min. ] i peak in response to VEGF165 was not inhibited by 2-APB, and in UAEC from non-pregnant animals there was even a dose-dependent increase in the percentage of cells producing the initial transient Ca 2C response to VEGF165 (Fig. 5C ), UAEC from both non-pregnant and pregnant animals subsequently displayed a dose-dependent decrease in the sustained Ca 2C response, indicated by a reduction in AUC response (Fig.  5D) , as expected. The occurrence of repeated periodic maxima was also seen to return to near baseline levels in the otherwise sustained-phase response of UAEC from pregnant animals when the maximal dose of VEGF165 was added with 2-APB (Fig. 6 ). This may further indicate that the apparently continuous sustained phase in response to VEGF165 alone may be comprised of fused bursts. Consistent with this, we have also seen more discretely repeated bursts in response to sub-maximal stimulation when using a lower dose of VEGF165 (%1 ng/ml) in the absence of 2-APB (Fig. 6) .
The Ca 2C response antagonists U73122 and 2-APB also inhibit VEGF165-stimulated eNOS activity
To further determine whether the VEGF165-stimulated eNOS activity is indeed dependent on Ca
2C
, UAEC from both non-pregnant and pregnant animals were again pretreated with the two Ca 2C response inhibitors described earlier, U73122 or 2-APB, and VEGF165-stimulated eNOS activity was measured. With both inhibitors, UAEC from both non-pregnant and pregnant animals showed a dose-dependent decrease in eNOS activity ( Fig. 7A and B) . For U73122, the dose-response curves for percentage inhibition for UAEC from both non-pregnant and pregnant animals were nearly identical. However, a higher dose of U73122 was required to completely block is dependent on Src but not ERK activity. UAEC from non-pregnant animals (nZ5 dishes) and UAEC from pregnant animals (nZ5 dishes) were treated for 30 min with 10 ng/ml VEGF165, which was preceded by a 25-min treatment with 1 mM VEGFR2 kinase inhibitor (VEGFRi), or a 20-min pretreatment with 10 mM PP2 or 10 mM U0126. Cells were grown to 70% density, loaded with Fura-2, and 50-80 cells/dish were imaged for 30 min.
Results are the mean percentages of cells respondingGS.E.M. *P!0.05 versus control. 
Figure 4
Sustained Ca 2C responses to VEGF165 depend on extracellular Ca 2C influx. Ca 2C was removed from the experimental buffer and UAEC were treated with 10 ng/ml VEGF165 (A, P!0.001 for UAEC from non-pregnant animals (nZ5 dishes) versus UAEC from pregnant animals (nZ5 dishes) in the first 300 s, analyzed by paired t-test and one-way ANOVA). In B, quantification of AUC for UAEC from both non-pregnant and pregnant animals in the presence of Ca
2C
-free buffer versus normal buffer (nZ5 dishes per cell type, per treatment) is shown. Data are represented as dish meansGS.E.M. (*P!0.05 versus normal buffer of same cell type and # P!0.01 versus UAEC eNOS activity (10 mM) than was required to block the Ca 2C response (1 mM). Pretreatment with 2-APB also inhibited VEGF165-stimulated eNOS activity for UAEC from both non-pregnant and pregnant animals. At 10 mM, 2-APB caused equivalent reductions in eNOS activity, by roughly 40%. However, at 50 mM, 2-APB only reduced eNOS activity a further 10% in UAEC from pregnant animals whereas in UAEC from non-pregnant animals the response was completely blocked. In comparison, U73122 and 2-APB had minimal effects on eNOS phosphorylation at various sites previously implicated in the regulation of eNOS activity ( Supplementary Figs 1 and 2 , see section on supplementary data given at the end of this article).
Discussion
Our previous studies reported that UAECs do not display an observable Ca 2C response (Bird et al. 2000 , Gifford et al. 2003 to VEGF in primary culture, but this was undertaken using just one cell at a time with the basic photometry apparatus. does it strongly stimulate eNOS activity (Grummer et al. 2009 ). Nonetheless, while both VEGF165 and VEGF-E behaved almost identically in UAEC from pregnant animals in UAEC from non-pregnant animals twice as many cells responded to VEGF-E than to VEGF165. Those cells that gave a detectable Ca 2C response to VEGF-E also tended to give a more prolonged response, as indicated by the larger mean AUC in the subset of cells that responded (Table 1) . Because the only difference between VEGF165 and VEGF-E binding to VEGFRs is that VEGF165 binds both VEGFR1 and VEGFR2 and VEGF-E preferentially binds VEGFR2, these results would indicate a co-modulatory The dose responses to inhibitors of the IP3 signaling pathway for VEGF165-stimulated Ca 2C responses are shown. In A and B, dose responses for pretreatment for 20 min with the PLC inhibitor, U73122, for both UAEC from non-pregnant animals (nZ5 dishes) and UAEC from pregnant animals (nZ5 dishes), with 10 ng/ml VEGF165 stimulation, are shown (A, *P!0.05 versus control). Too few cells responded to VEGF165 at the 1 mM dose of U73122 to permit statistical analysis for area under the curve (AUC, (B) indicated by NA). In C and D, dose responses for pretreatment for 5 min with the IP3R antagonist, 2-APB, with 10 ng/ml VEGF165 in UAEC from nonpregnant animals (nZ5 dishes) and UAEC from pregnant animals (nZ5 dishes) are shown (C, *P!0.05 versus control, # P!0.05 versus same dose of 2-APB in UAEC from pregnant animals; D, *P!0.05 versus control). Data presented as meanGS.E.M. for all panels.
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Cell 3
Cell 2 Cell 1 Figure 6 Reducing the VEGF165-stimulated Ca 2C response signal reveals Ca 2C bursts. Using a submaximal dose of VEGF165 (1 ng/ml, cells 3 and 4) or 10 mM 2-APB pretreatment with 10 ng/ml VEGF165 (cells 1 and 2) revealed that Ca 2C burst responses may be fused in continuous Ca 2C responses to 10 ng/ml VEGF165 alone in UAEC from pregnant animals. Burst activity is also observed in UAEC from non-pregnant animals under similar conditions.
role for VEGFR1 over VEGFR2, as previously suggested (Grummer et al. 2009 ). Together, our findings indicate that VEGFR1 may indeed be acting as 'decoy receptor' in UAEC as others have suggested (Park et al. 1994) . Even though Grummer et al. (2009) reported that relative VEGFR1 and VEGFR2 expression levels are similar in UAEC from non-pregnant and pregnant animals, there still may be changes in co-localization that could account for these differences between the non-pregnant and pregnant state. Further studies would be needed to definitively address this question. Regarding the hypothesis that there is pregnancyspecific enhancement of CCE, even though the Ca 2C responses to VEGF overall show no clear differences in AUC between UAEC from non-pregnant and pregnant animals, removal of extracellular Ca 2C reveals that CCE plays a greater role in the VEGF Ca 2C response in UAEC from pregnant animals. Despite a lack of discrete synchronous bursting by neighboring cells as previously observed in response to ATP (Yi et al. 2010a,b) , UAEC from pregnant animals show more coordinated and timely initiation of a Ca 2C response to VEGF165 and are more capable of producing a coordinated early Ca 2C peak compared with UAEC from non-pregnant animals. Previously, we used U73122 (a PLC inhibitor) and 2-APB (an IP3R/TRPC activation antagonist) to implicate IP3 as a key mediator in the Ca 2C response to ATP (Sullivan et al. 2006) . As shown here, both inhibitors work in a similar manner to inhibit the VEGF165-stimulated Ca 2C response in UAEC as they do with ATP. While U73122
gives a total inhibition of the Ca 2C response, 2-APB more selectively inhibits the sustained phase. At the higher doses used in this study, 2-APB even augments cell recruitment in response to 10 ng/ml VEGF165, but Ca 2C responses only remained elevated above basal levels for a duration corresponding closely with the initial endoplasmic reticulum Ca 2C release alone (in the absence of extracellular Ca 2C ). These observations alone beg the question of whether VEGF activation of PLCg may in turn evoke a Ca 2C response through interaction of at least one of the IP3R and TRP isoforms already known to be present in UAEC. Others have reported VEGF signaling through TRPC6 (Ge et al. 2009) , an isoform which is present in UAEC (Gifford et al. 2006a) . One criticism that could be raised is that the co-immunoprecipitation (IP) studies of IP3R2 and TRPC3 coupling observed in response to ATP revealed no such co-IP for VEGF (Gifford et al. 2006a to fuse into a singular, sustained Ca 2C response with only minor periodic maxima. While our data are highly consistent with an IP3R/TRPC burst mechanism previously identified in response to ATP, the subtypes of IP3R and TRPC involved in responses to VEGF remain unknown at this time, and certainly further studies are warranted. The final hypothesis (in UAEC from pregnant animals challenged with VEGF a greater role for CCE underlies pregnancy-adapted NO output) is the hardest to address. Certainly the eNOS phosphorylation state previously reported (Grummer et al. 2009 ) is not substantially different in between UAEC from non-pregnant and pregnant animals on VEGF challenge. If we also consider the recent description of eNOS sensitivity to elevated [Ca 2C ] i in various phosphorylation states (Tran et al. 2009 ), then the minimal [Ca 2C ] i levels necessary for eNOS activation would be predicted to be roughly 90-100 nM.
As indicated in Fig. 1D , UAEC from pregnant animals are Inhibitors of VEGF165-stimulated Ca 2C responses inhibit eNOS activity.
eNOS activity was measured by arginine-to-citrulline conversion assay. UAEC from non-pregnant animals (nZ4/dose) and UAEC from pregnant animals (nZ4/dose) were pretreated with inhibitor for 5 min, followed by a 10-min treatment with 10 ng/ml VEGF165. (A) Cells were treated with 0.1, 1, or 10 mM U73122. (B) Cells were treated with 1, 10, or 50 mM 2-APB. Data for both panels presented as meanGS.E.M. (*P!0.05 versus control).
more likely to reach these levels in response to VEGF165 than UAEC from non-pregnant animals, and certainly both U73122 and 2-APB inhibition of eNOS activity only begins at doses where these drugs also measurably inhibit the Ca 2C response. Therefore, it seems likely that pregnancy-specific changes in the VEGF-stimulated Ca 2C response coordinate the Ca 2C response in UAEC from pregnant animals, resulting in an earlier and higher maxima, may indeed contribute to the pregnancy adapted NO output (Table 1) . What remains unclear is whether such changes in CCE alone can fully account for pregnancy-adapted changes in eNOS activation, or whether other events such as eNOS phosphorylation may also still contribute. The Ca 2C response in UAEC at the submaximal but physiological dose of 1 ng/ml VEGF165 may be important in further addressing this point. According to Grummer et al. (2009) , 1 ng/ml of VEGF165 was the lowest dose that gave a significant increase in eNOS activation in UAEC from pregnant animals compared with UAEC from non-pregnant animals. Herein, we also show that there is indeed a significant difference in number of Ca 2C responders between UAEC from non-pregnant animals and UAEC from pregnant animals on stimulation with the same 1 ng/ml dose of VEGF165 (Fig. 2) . In the UAEC from pregnant animals the number of Ca 2C signaling responders to 1 ng/ml VEGF165 is not only greater but also closer to maximal than in UAEC from non-pregnant animals.
The difference observed at the 1 ng/ml dose alone is in contrast to the eNOS activity data from Grummer et al. (2009) , which showed clearly that UAEC from pregnant animals were more able to activate eNOS than UAEC from non-pregnant animals at all doses tested equal to or over 1 ng/ml. In addition, while blocking Ca 2C responses using U73122 or 2-APB is certainly inhibitory to eNOS activation, it is not fully inhibitory. Taken together, these results indicate that while Ca 2C mobilization may be critically important for enabling eNOS activation in response to VEGF165, and is necessary for maximal activation, it is probably not the sole regulator. It should also be remembered Ca 2C responses to VEGF-E are observed in far more UAEC from non-pregnant animals than UAEC from pregnant animals and yet eNOS activation is not greater (Grummer et al. 2009 ). Therefore, other mechanisms, such as kinase-mediated eNOS phosphorylation, could still be playing an important role in pregnancy-adaptive programing. Previous studies by others regarding the role of phosphorylation in regulation of eNOS activation showed that dual phosphorylation optimally increased efficiency of electron transfer through the eNOS dimer in the presence of calmodulin, thereby shifting the [Ca 2C ] i sensitivity in the physiological range to the left (Tran et al. 2009 ). Thus, elevated Ca 2C and an optimal eNOS phosphorylation state combined can lower the eNOS activation threshold and achieve significant eNOS activity even at more modest [Ca 2C ] i elevation. Grummer et al.
(2009) examined the effect of 10 ng/ml VEGF165 on multiple eNOS phosphorylation sites and established that any modest differences in phosphorylations at multiple eNOS residues were not significant between UAEC from non-pregnant and pregnant animals. It was not determined if those events were paired on the same eNOS molecule, or if this changed between the NP-and P-state. Thus, while it was concluded that eNOS phosphorylation alone is unlikely to be the key regulator of pregnancy-adapted changes in eNOS activation, the results of this study, together with the findings of Grummer et al. (2009) , indicate subtle changes in dual eNOS phosphorylation combined with subtle changes in the Ca 2C response most probably account for pregnancyspecific increases in VEGF activation of eNOS in UAEC.
Conclusion
While it is clear that regulation of pregnancy-adapted changes in eNOS activity in UAEC in response to VEGF may be more complex than originally thought, our findings indicate that pregnancy-induced changes in Ca 2C signaling in response to VEGF occur in UAEC from pregnant animals and probably involve changes in sustained-phase capacitative burst responses operating throughout the cell, as reported previously for pregnancy-specific changes in Ca 2C response to ATP (Yi et al. 2010a) . Since inhibitors of the Ca 2C response (U73122 and 2-APB) were both able to inhibit VEGF165-stimulated eNOS activity, we can also conclude that elevated [Ca 2C ] i , specifically via CCE, is critically important for eNOS activation in response to VEGF165, just as it is for ATP. However, it is unlikely in the case of VEGF that these changes alone fully explain pregnancy-adapted changes in NO production by UAEC from pregnant animals i.e. such changes in Ca 2C signaling may be necessary, but they are not sufficient. Combined with the findings of Grummer et al. (2009) it seems most likely that VEGF subtly influences the overall eNOS phosphorylation state to create more dual-phosphorylated eNOS molecules to enhance the [Ca 2C ] i sensitivity of NO production, as proposed by Tran et al. (2009) have otherwise failed and associated vasodilation is lacking (Krupp et al. 2013) .
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